Because of the ability of proteasome inhibitors to block NF-kB activity, we investigated expression of some established NF-kB target genes, including BAX (BCL2-Associated X Protein), BCL-2 (B-Cell CLL/Lymphoma 2), NFKB2 (Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2 (P49/P100)), c-FLIP (CASP8 And FADD-Like Apoptosis Regulator) and IL-8. The gene discussed is NFKB1; the disease is lymphoma.